Search

Your search keyword '"Van Geertruyden, Jean"' showing total 582 results
Start Over Author "Van Geertruyden, Jean" Language english
582 results on '"Van Geertruyden, Jean"'

4. Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised, phase 2 trial

Author

Larivière, Ynke, Matuvanga, Trésor Zola, Osang'ir, Bernard Isekah, Milolo, Solange, Meta, Rachel, Kimbulu, Primo, Robinson, Cynthia, Katwere, Michael, McLean, Chelsea, Lemey, Gwen, Matangila, Junior, Maketa, Vivi, Mitashi, Patrick, Van geertruyden, Jean-Pierre, Van Damme, Pierre, and Muhindo-Mavoko, Hypolite

Published
2024
Full Text
View/download PDF

5. Impact of population based indoor residual spraying in combination with mass drug administration on malaria incidence and test positivity in a high transmission setting in north eastern Uganda

Author

Mulebeke Ronald, Wanzira Humphrey, Yeka Adoke, and Van Geertruyden Jean-Pierre

Subjects
Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Mass drug administration (MDA) and indoor residual spraying (IRS) are potent malaria burden reduction tools. The impact of combining MDA and IRS is not well documented. We evaluated the impact of MDA + IRS compared to IRS alone at a high transmission site in Eastern Uganda. Methods A quasi-experimental study was implemented in Toroma and Kapujan subcounties in north eastern Uganda. Both subcounties received four rounds of IRS using primiphos-methyl (Acttellic SC300) 6–8 months apart from December 2016 to December 2018. Eligible residents of Kapujan simultaneously received MDA using dihydroartemesinin-piperaquine (DHA-PQ). Health facility data was used to monitor malaria case incidence rate and test positivity rates. Results In the MDA + IRS arm, malaria incidence dropped by 83% (IRR: 0·17 (0.16–0.18); p

Published
2023
Full Text
View/download PDF

9. Implementation research of a cluster randomized trial evaluating the implementation and effectiveness of intermittent preventive treatment for malaria using dihydroartemisinin-piperaquine on reducing malaria burden in school-aged children in Tanzania: methodology, challenges, and mitigation

Author

Makenga, Geofrey, Seth, Misago D., Baraka, Vito, Mmbando, Bruno P., Challe, Daniel P., Francis, Filbert, Mhina, Athanas, Minja, Daniel T. R., Chiduo, Mercy, Mandara, Celine, Liheluka, Edwin, Gesase, Samwel, Segeja, Method, Mtove, George, Kamugisha, Mathias, Lusasi, Abdallah, Chacky, Frank, David, Anna, Thawer, Sumaiyya, Mohamed, Ally, Lazaro, Samwel, Molteni, Fabrizio, Nkayamba, Alex, Van geertruyden, Jean-Pierre, and Lusingu, John P. A.

Published
2023
Full Text
View/download PDF

13. Population pharmacokinetics of amodiaquine and piperaquine in African pregnant women with uncomplicated Plasmodium falciparum infections.

Author

Ding, Junjie, Hoglund, Richard M., Tagbor, Harry, Tinto, Halidou, Valéa, Innocent, Mwapasa, Victor, Kalilani‐Phiri, Linda, Van Geertruyden, Jean‐Pierre, Nambozi, Michael, Mulenga, Modest, Hachizovu, Sebastian, Ravinetto, Raffaella, D'Alessandro, Umberto, and Tarning, Joel

Subjects
SECOND trimester of pregnancy, PREGNANT women, THIRD trimester of pregnancy, GESTATIONAL age, PLASMODIUM falciparum
Abstract

Artemisinin‐based combination therapy (ACT) is the first‐line recommended treatment for uncomplicated malaria. Pharmacokinetic (PK) properties in pregnant women are often based on small studies and need to be confirmed and validated in larger pregnant patient populations. This study aimed to evaluate the PK properties of amodiaquine and its active metabolite, desethylamodiaquine, and piperaquine in women in their second and third trimester of pregnancy with uncomplicated P. falciparum infections. Eligible pregnant women received either artesunate‐amodiaquine (200/540 mg daily, n = 771) or dihydroartemisinin‐piperaquine (40/960 mg daily, n = 755) for 3 days (NCT00852423). Population PK properties were evaluated using nonlinear mixed‐effects modeling, and effect of gestational age and trimester was evaluated as covariates. 1071 amodiaquine and 1087 desethylamodiaquine plasma concentrations, and 976 piperaquine plasma concentrations, were included in the population PK analysis. Amodiaquine concentrations were described accurately with a one‐compartment disposition model followed by a two‐compartment disposition model of desethylamodiaquine. The relative bioavailability of amodiaquine increased with gestational age (1.25% per week). The predicted exposure to desethylamodiaquine was 2.8%–32.2% higher in pregnant women than that reported in non‐pregnant women, while day 7 concentrations were comparable. Piperaquine concentrations were adequately described by a three‐compartment disposition model. Neither gestational age nor trimester had significant impact on the PK of piperaquine. The predicted exposure and day 7 concentrations of piperaquine were similar to that reported in non‐pregnant women. In conclusion, the exposure to desethylamodiaquine and piperaquine was similar to that in non‐pregnant women. Dose adjustment is not warranted for women in their second and their trimester of pregnancy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Evaluating the effectiveness of enhanced family planning education on knowledge and use of family planning in fishing communities of Lake Victoria in Uganda: a randomized controlled trial

Author

Nanvubya, Annet, Wanyenze, Rhoda K., Abaasa, Andrew, Nakaweesa, Teddy, Mpendo, Juliet, Kawoozo, Barbarah, Matovu, Francis, Nabukalu, Sarah, Omoding, Geoffrey, Kaweesi, Jed, Ndugga, John, Bagaya, Bernard, Chinyenze, Kundai, Price, Matt A., and Van Geertruyden, Jean Pierre

Published
2022
Full Text
View/download PDF

21. Healthcare Providers' and Frontline Workers' Experiences of an Ebola Vaccine Trial in the Boende Health District of the Democratic Republic of the Congo.

Author

Zola Matuvanga, Trésor, Bikioli Bolombo, Freddy, Paviotti, Antea, Larivière, Ynke, Lemey, Gwen, Salloum, Maha, Isekah Osang'ir, Bernard, Matangila, Junior, Maketa, Vivi, Esanga, Emmanuel, Milolo, Solange, Mitashi, Patrick, Van Damme, Pierre, Muhindo-Mavoko, Hypolite, and Van Geertruyden, Jean-Pierre

Published
2024
Full Text
View/download PDF

24. Effectiveness and safety of intermittent preventive treatment for malaria using either dihydroartemisinin-piperaquine or artesunate-amodiaquine in reducing malaria related morbidities and improving cognitive ability in school-aged children in Tanzania: A study protocol for a controlled randomised trial

Author

Makenga, Geofrey, Baraka, Vito, Francis, Filbert, Nakato, Swabra, Gesase, Samwel, Mtove, George, Madebe, Rashid, Kyaruzi, Edna, Minja, Daniel T.R., Lusingu, John P.A., and Van geertruyden, Jean-Pierre

Published
2020
Full Text
View/download PDF

32. Efficacy and safety of re-treatment with the same artemisinin-based combination treatment (ACT) compared with an alternative ACT and quinine plus clindamycin after failure of first-line recommended ACT (QUINACT): a bicentre, open-label, phase 3, randomised controlled trial

Author

Mavoko, Hypolite Muhindo, Nabasumba, Carolyn, da Luz, Raquel Inocêncio, Tinto, Halidou, D'Alessandro, Umberto, Kambugu, Andrew, Baraka, Vito, Rosanas-Urgell, Anna, Lutumba, Pascal, and Van geertruyden, Jean-Pierre

Published
2017
Full Text
View/download PDF

37. Researchers' responsibilities in resource-constrained settings: experiences of implementing an ancillary care policy in a vaccine trial in the Democratic Republic of the Congo.

Author

Lemey, Gwen, Zola, Trésor, Larivière, Ynke, Milolo, Solange, Danoff, Engbu, Bakonga, Lazarre, Esanga, Emmanuel, Vermeiren, Peter, Maketa, Vivi, Matangila, Junior, Mitashi, Patrick, Van Damme, Pierre, Van geertruyden, Jean-Pierre, Ravinetto, Raffaella, and Muhindo-Mavoko, Hypolite

Subjects
VACCINE trials, RESEARCH personnel, INSURANCE policies, INFORMED consent (Medical law), TRADITIONAL medicine, INSURANCE crimes, TRAFFIC accidents, WELL-being
Abstract

In this paper, we discuss challenges associated with implementing a policy for Ancillary Care (AC) for related and unrelated (serious) adverse events during an Ebola vaccine trial conducted in a remote area of the Democratic Republic of the Congo. Conducting clinical trials in resourceconstrained settings can raise context-related challenges that have implications for study participants' health and wellbeing. During the Ebola vaccine study, three participants were injured in road traffic accidents, but there were unexpected difficulties when trying to apply the AC policy. First, because of the nature of the adverse events, the insurer refused to cover the costs. Second, the AC policy did not address treatments by traditional medicine, even though traditional medicines are frequently used and highly trusted in the study community. This highlighted a contrast between the researchers' well-intentioned AC approach and the participants' legitimate preferences. The way in which researchers should address their responsibility to provide AC is not straightforward; it requires contextualization. Our experience highlights the importance of involving community representatives and the local ethics committee to ensure development of an AC policy that is culturally and ethically appropriate. Additionally, the insurance contract should clearly stipulate which adverse events are linked to the trial participation, and thus eligible for coverage, to avoid controversies when claims are made. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

44. Artemisinin-based combination therapy during pregnancy: outcome of pregnancy and infant mortality: a cohort study

Author

Nambozi, Michael, Tinto, Halidou, Mwapasa, Victor, Tagbor, Harry, Kabuya, Jean-Bertin Bukasa, Hachizovu, Sebastian, Traoré, Maminata, Valea, Innocent, Tahita, Marc Christian, Ampofo, Gifty, Buyze, Jozefien, Ravinetto, Raffaella, Arango, Diana, Thriemer, Kamala, Mulenga, Modest, van Geertruyden, Jean-Pierre, and D’Alessandro, Umberto

Published
2019
Full Text
View/download PDF

45. Dietary outcomes of community-based CVD preventive interventions: a systematic review and meta-analysis.

Author

Hassen, Hamid Y, Sisay, Binyam G, Van Geertruyden, Jean-Pierre, Le Goff, Delphine, Ndejjo, Rawlance, Musinguzi, Geofrey, Abrams, Steven, and Bastiaens, Hilde

Subjects
DATABASE searching, HEALTH education, CINAHL database, HEALTH promotion, NON-communicable diseases, EPIDEMIOLOGICAL transition
Abstract

Objective: We aimed to synthesise available evidence on the effects of community-based interventions in improving various dietary outcome measures. Design: Systematic review and meta-analysis. Setting: We searched databases including Medline, EMBASE, PSYCINFO, CINAHL and the Cochrane registry for studies reported between January 2000 and June 2022. The methodological quality of the included studies was evaluated using the Cochrane risk of bias tools for each study type. For some of the outcomes, we pooled the effect size using a random-effects meta-analysis. Participants: A total of fifty-one studies, thirty-three randomised and eighteen non-randomised, involving 100 746 participants were included. Results: Overall, thirty-seven studies found a statistically significant difference in at least one dietary outcome measure favouring the intervention group, whereas fourteen studies found no statistically significant difference. Our meta-analyses indicated that, compared with controls, interventions were effective in decreasing daily energy intake (MJ/d) (mean difference (MD): –0·25; 95 % CI: –0·37, –0·14), fat % of energy (MD: –1·01; 95 % CI: –1·76, –0·25) and saturated fat % of energy (MD: –1·54; 95 % CI: –2·01, –1·07). Furthermore, the interventions were effective in improving fibre intake (g/d) (MD: 1·08; 95 % CI: 0·39, 1·77). Effective interventions use various strategies including tailored individual lifestyle coaching, health education, health promotion activities, community engagement activities and/or structural changes. Conclusion: This review shows the potential of improving dietary patterns through community-based CVD preventive interventions. Thus, development and implementation of context-specific preventive interventions could help to minimise dietary risk factors, which in turn decrease morbidity and mortality due to CVD and other non-communicable diseases. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Pre-vaccination monocyte-to-lymphocyte ratio as a biomarker for the efficacy of malaria candidate vaccines: A subgroup analysis of pooled clinical trial data.

Author

Nyandele, Jane Paula, Kibondo, Ummi Abdul, Issa, Fatuma, Van Geertruyden, Jean Pierre, Warimwe, George, Jongo, Said, Abdulla, Salim, and Olotu, Ally

Subjects
MONOCYTE lymphocyte ratio, MALARIA vaccines, MALARIA, VACCINE effectiveness, CLINICAL trials, VACCINE trials
Abstract

Background: Pre-vaccination monocyte-to-lymphocyte ratio was previously suggested as a marker for malaria vaccine effectiveness. We investigated the potential of this cell ratio as a marker for malaria vaccine efficacy and effectiveness. Effectiveness was investigated by using clinical malaria endpoint, and efficacy was investigated by using surrogate endpoints of Plasmodium falciparum prepatent period, parasite density, and multiplication rates in a controlled human malaria infection trial (CHMI). Methods: We evaluated the correlation between monocyte-to-lymphocyte ratio and RTS,S vaccine effectiveness using Cox regression modeling with clinical malaria as the primary endpoint. Of the 1704 participants in the RTS,S field trial, data on monocyte-to-lymphocyte ratio was available for 842 participants, of whom our analyses were restricted. We further used Spearman Correlations and Cox regression modeling to evaluate the correlation between monocyte-to-lymphocyte ratio and Whole Sporozoite malaria vaccine efficacy using the surrogate endpoints. Of the 97 participants in the controlled human malaria infection vaccine trials, hematology and parasitology information were available for 82 participants, of whom our analyses were restricted. Results: The unadjusted efficacy of RTS,S malaria vaccine was 54% (95% CI: 37%-66%, p <0.001). No correlation was observed between monocyte-to-lymphocyte ratio and RTS,S vaccine efficacy (Hazard Rate (HR):0.90, 95%CI:0.45–1.80; p = 0.77). The unadjusted efficacy of Whole Sporozoite malaria vaccine in the appended dataset was 17.6% (95%CI:10%-28.5%, p<0.001). No association between monocyte-to-lymphocyte ratio and the Whole Sporozoite malaria vaccine was found against either the prepatent period (HR = 1.16; 95%CI:0.51–2.62, p = 0.72), parasite density (rho = 0.004, p = 0.97) or multiplication rates (rho = 0.031, p = 0.80). Conclusion: Monocyte-to-lymphocyte ratio alone may not be an adequate marker for malaria vaccine efficacy. Further investigations on immune correlates and underlying mechanisms of immune protection against malaria could provide a clearer explanation of the differences between those protected in comparison with those not protected against malaria by vaccination. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Low seroprevalence of Ebola virus in health care providers in an endemic region (Tshuapa province) of the Democratic Republic of the Congo.

Author

Zola Matuvanga, Trésor, Mariën, Joachim, Larivière, Ynke, Osang'ir, Bernard Isekah, Milolo, Solange, Meta, Rachel, Esanga, Emmanuel, Maketa, Vivi, Matangila, Junior, Mitashi, Patrick, Ahuka Mundeke, Steve, Muhindo-Mavoko, Hypolite, Muyembe Tamfum, Jean-Jacques, Van Damme, Pierre, and Van Geertruyden, Jean-Pierre

Subjects
MEDICAL personnel, EBOLA virus, SEROPREVALENCE, VACCINE trials, EBOLA virus disease, VIRAL antibodies
Abstract

Introduction: A serosurvey among health care providers (HCPs) and frontliners of an area previously affected by Ebola virus disease (EVD) in the Democratic Republic of the Congo (DRC) was conducted to assess the seroreactivity to Ebola virus antigens. Methods: Serum samples were collected in a cohort of HCPs and frontliners (n = 698) participants in the EBL2007 vaccine trial (December 2019 to October 2022). Specimens seroreactive for EBOV were confirmed using either the Filovirus Animal Nonclinical Group (FANG) ELISA or a Luminex multiplex assay. Results: The seroreactivity to at least two EBOV-Mayinga (m) antigens was found in 10 (1.4%: 95% CI, 0.7–2.6) samples for GP-EBOV-m + VP40-EBOV-m, and 2 (0.3%: 95% CI, 0.0–1.0) samples for VP40-EBOV-m + NP-EBOV-m using the Luminex assay. Seroreactivity to GP-EBOV-Kikwit (k) was observed in 59 (8.5%: 95%CI, 6.5–10.9) samples using FANG ELISA. Conclusion: In contrast to previous serosurveys, a low seroprevalence was found in the HCP and frontline population participating in the EBL2007 Ebola vaccine trial in Boende, DRC. This underscores the high need for standardized antibody assays and cutoffs in EBOV serosurveys to avoid the broad range of reported EBOV seroprevalence rates in EBOV endemic areas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results